Notice of Special Interest (NOSI): Administrative Supplements for NCI Division of Cancer Biology Research Programs

Funding Agency:
National Institutes of Health

The Division of Cancer Biology (DCB) at the National Cancer Institute (NCI) announces the opportunity for current awardees of DCB led programs to apply for supplemental funding to support collaborative research projects. DCB led or co-led programs appropriate for this opportunity include the Acquired Resistance to Therapy Network (ARTNet), the Cancer Systems Biology Consortium (CSBC), the Cancer Tissue Engineering Collaborative (TEC), the Cellular Cancer Biology Imaging Research (CCBIR) program, the Epstein Barr Virus Associated Lymphoma Consortium (EALC), the Metabolic Dysregulation and Cancer Risk Program (MeDoC), the Metastasis Research Network (MetNet), the Onco-Aging Consortium (OAC), the Oncology Models Forum (OMF), the Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium (PSRC), the Patient-Derived Models of Cancer Program (PDMC), the Pediatric Immunotherapy Network (PIN), the Physical Sciences-Oncology Network (PS-ON), the Program on the Origins of Gastroesophageal Cancers, and the Translational and Basic Science Research in Early Lesions (TBEL) consortium.

The Division of Cancer Biology (DCB) at the National Cancer Institute (NCI) supports a broad range of basic and preclinical research through investigator-initiated projects and focused programs that target specific questions and challenges in cancer biology. These programs include the Acquired Resistance to Therapy Network (ARTNet), the Cancer Systems Biology Consortium (CSBC), the Cancer Tissue Engineering Collaborative (TEC), the Cellular Cancer Biology Imaging Research (CCBIR) program, the Epstein Barr Virus Associated Lymphoma Consortium (EALC), the Metabolic Dysregulation and Cancer Risk Program (MeDoC), the Metastasis Research Network (MetNet), the Onco-Aging Consortium (OAC), the Oncology Models Forum (OMF), the Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium (PSRC), the Patient-Derived Models of Cancer Program (PDMC), the Pediatric Immunotherapy Network (PIN), the Physical Sciences-Oncology Network (PS-ON), the Program on the Origins of Gastroesophageal Cancers, and the Translational and Basic Science Research in Early Lesions (TBEL) consortium.

This NOT announces the opportunity for current awardees of DCB led programs to apply for supplemental funding to support collaborative research projects. Collaborative projects can include investigators within one consortium, across consortia, and/or may include investigators who are not currently supported by the DCB research programs listed above but are collaborating with a member of a DCB led or co-led consortium (i.e. Associate Members). The programmatic goals of each research program may differ; therefore, it is highly recommended that potential applicants contact their NCI Program Director before applying to ensure collaborative projects reflect program priorities.

All requests, regardless of parent award funding mechanism, must be received by 5:00 PM local time on April 12, 2024. This is a one-time announcement. Late applications will not be accepted.

NOT-CA-24-029

Eligibility

Faculty

Category

Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

April 12, 2024